Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061

americanpharmaceuticalreviewAugust 24, 2017

Tag: osteoarthritis disease , Symic Bio , SB-061

PharmaSources Customer Service